US · Healthcare · Biotechnology
EPS came in at -0.08 against a street estimate of -0.06 — a miss of 33.3%.
Analysts rate Lexaria Bioscience Corp a buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $52.50.
| Fund | Stake |
|---|---|
| Invenomic Capital Management, LP | 1.78% |
| Geode Capital Management, LLC | 1.18% |
| Vanguard Capital Management, LLC | 0.89% |
| Citadel Advisors Llc | 0.63% |
| The Toronto-Dominion Bank | 0.56% |
| Vanguard Fiduciary Trust Co | 0.38% |
| UBS Group AG | 0.21% |
| State Street Corp | 0.16% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lexaria Bioscience Corp — free to start.
Google PlayApp StoreData updated 2026-09-18.